Where does Vitae Pharmaceuticals, LLC rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Vitae Pharmaceuticals, LLC ranks #6,973 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Vitae Pharmaceuticals, LLC hold?

Vitae Pharmaceuticals, LLC holds 48 US utility patents granted between 2015 and 2025, spanning 6 technology areas.

What is Vitae Pharmaceuticals, LLC's Innovation Score?

Vitae Pharmaceuticals, LLC has an Innovation Score of 35.4 out of 100 (top 49% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Vitae Pharmaceuticals, LLC focus on?

Vitae Pharmaceuticals, LLC's top technology area is C07D (Heterocyclic Compounds) with 48 patents, ranking #163 of 3,165 assignees active in that subclass. Grants appear in 6 CPC subclasses total.

Is Vitae Pharmaceuticals, LLC's patent grant rate increasing or decreasing?

Vitae Pharmaceuticals, LLC's recent grant velocity is -66% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Vitae Pharmaceuticals, LLC's patents?

Vitae Pharmaceuticals, LLC's patents average 18.1 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Vitae Pharmaceuticals, LLC patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Vitae Pharmaceuticals, LLC

USPTO PatentsView assignee record - 48 granted patents across 6 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07D (Heterocyclic Compounds).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Vitae ranks #6,973 of 49,997 tracked US assignees by granted-patent volume, with 48 patents across 6 technology areas.

#6,973
of 49,997 US assignees by volume: Top 49%
by Innovation Score (35.4/100): 18.1
avg claims per patent: -66%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R6973 · US Corporation #6,973 · 48 grants

GRANTS-SMALL · UPPER-Q · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-USCORP · VEL-DROP · BOOK-FULL

GRANTS-SMALL 48 grants
UPPER-Q #6,973/49,997
PHOTO-FINISH Vapotherm
CPC-NARROW C07D · 6 areas
INNOV-THIN 35.4/100
CLAIMS-RICH 18.1 claims/avg
TYPE-USCORP US Corporation
VEL-DROP -66% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Vapotherm, Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Vitae’s 35.4 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 13.4 pts (38%) Velocity 2.4 pts (7%) Breadth 8.7 pts (25%) Claim depth 10.9 pts (31%)

Qualcomm Incorporated · highest

85
Anacor Pharmaceuticals · near

35
Hitachi Information… · near

35
Quotient Technology · near

35
Vitae Pharmaceuticals · this assignee

35
Neutrik · near

35
3D Lighting… · lowest

7

What this shows Vitae's Innovation Score is 35.4/100 (top 49% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Vitae?

Each dot is one of Vitae’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Vitae’s own 18.1 claims/patent is ABOVE the 17.6 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Vitae vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Vitae's grants concentrate

Vitae Pharmaceuticals, LLC is a focused PatentsView assignee: 6 CPC subclasses with 100% of grants classified under C07D (Heterocyclic Compounds). Peak complete grant year is 2015 (13 grants) versus a trough of 1 in 2023. By volume, Vitae sits between Vapotherm, Inc. and Xinjiang Goldwind Science & Technology Co., Ltd..

Vitae's three-year grant acceleration

Vitae Pharmaceuticals, LLC shows 4 grants in 2022–2024 against only 11 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Vapotherm

48
Verinata Health

48
Victoria Link

48
Virent

48
Vive Health

48
Weta Digital

48
Wika Alexander Wi…

48
Xinjiang Goldwind…

48
Vitae Pharmaceuti… ◀

48

What this shows Vitae holds 48 patents at rank #6,972, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Vitae

By rank, the assignees closest to #6,972 in granted patent volume.

Leaders in C07D (Heterocyclic Compounds)

Other assignees with the most granted patents in Vitae's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Vitae, neither rank-band nor same-CPC leaders (those blocks stay above). In C07D (Heterocyclic Compounds), Vitae ranks #163 of 3,165 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (35 here).

Neutrik AG 35 Anacor Pharmaceuticals, LLC 35 Hitachi Information AND Telecommunication Engineering, Ltd. 35 Quotient Technology Inc. 35

Vitae's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

35 Top 49% higher than 51% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Vitae Pharmaceuticals, LLC patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	13	27.1%
2016	7	14.6%
2017	7	14.6%
2018	5	10.4%
2019	3	6.3%
2020	4	8.3%
2021	4	8.3%
2022	2	4.2%
2023	1	2.1%
2024	1	2.1%
2025partial year	1	2.1%

Which technologies does Vitae Pharmaceuticals, LLC patent most?

C07D - Heterocyclic Compounds 48

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 42

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 14

C07B - General Methods OF Organic CHEMISTRY; Apparatus Therefor 6

C07F - Acyclic, Carbocyclic OR Heterocyclic Compounds Containing Elements Other Than Carbon, Hydrogen, Halogen, Oxygen, Nitrogen, Sulfur, Selenium OR Tellurium 6

C07C - Acyclic OR Carbocyclic Compounds 4

Top 6 of 6 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Vitae Pharmaceuticals, LLC's patent record in context - here's where to go next.

Vitae Pharmaceuticals, LLC's lead technology class is C07D (Heterocyclic Compounds), 100% of its portfolio - see every assignee active in that class. Explore C07D
Ranked #6,973 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Vitae Pharmaceuticals, LLC against Vapotherm, Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 35.4/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.